» Articles » PMID: 28356109

Systematic Review and Meta-analysis of Mortality of Patients Infected with Carbapenem-resistant Klebsiella Pneumoniae

Overview
Publisher Biomed Central
Date 2017 Mar 31
PMID 28356109
Citations 259
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Carbapenem resistant K. pneumoniae (CRKP) has aroused widespread attention owing to its very limited therapeutic options, and this strain has increased rapidly in recent years. Although it is accepted that drug resistance is associated with increased mortality in general, but some other studies found no such relationship. To estimate mortality of patients infected with CRKP in general and analyze factors for mortality of this infection, thus, we conducted this systematic review and meta-analysis.

Methods: A systematic literature review of relevant studies published until December 2015 was conducted. We selected and assessed articles reporting mortality of patients infected with CRKP.

Results: Pooled mortality was 42.14% among 2462 patients infected with CRKP versus 21.16% in those infected with carbapenem-susceptible K. pneumoniae (CSKP). The mortality of patients with bloodstream infection (BSI) or urinary tract infection was 54.30 and 13.52%, respectively, and 48.9 and 43.13% in patients admitted to the intensive care unit (ICU) or who underwent solid organ transplantation (SOT). Mortality was 47.66% in patients infected with K. pneumoniae carbapenemase-producing K. pneumoniae and 46.71% in those infected with VIM-producing K. pneumoniae. Geographically, mortality reported in studies from North America, South America, Europe, and Asia was 33.24, 46.71, 50.06, and 44.82%, respectively.

Conclusions: Our study suggests that patients infected with CRKP have higher mortality than those infected with CSKP, especially in association with BSI, ICU admission, or SOT. We also considered that patients' survival has a close relationship with their physical condition. Our results imply that attention should be paid to CRKP infection, and that strict infection control measures and new antibiotics are required to protect against CRKP infection.

Citing Articles

Caspase-11 and NLRP3 exacerbate systemic Klebsiella infection through reducing mitochondrial ROS production.

Zhou Y, Chai Z, Pandeya A, Yang L, Zhang Y, Zhang G Front Immunol. 2025; 16:1516120.

PMID: 40034692 PMC: 11873083. DOI: 10.3389/fimmu.2025.1516120.


Comparative analysis of clinical characteristics and outcomes between carbapenem-resistant and carbapenem-sensitive infections: insights from a tertiary hospital in Northern China.

Wang B, Zhang W, Zhang H, Li M, Zhang Z, Peng X Front Med (Lausanne). 2025; 12:1499057.

PMID: 39975685 PMC: 11836024. DOI: 10.3389/fmed.2025.1499057.


Comparison of the in vitro activities and resistance mechanisms against imipenem-relebactam and ceftazidime-avibactam in clinical KPC-producing Klebsiella pneumoniae isolated in China.

Guo Y, Yao L, Wang J, Zhang Y, Zhuo C, Wang Y Infection. 2025; .

PMID: 39954208 DOI: 10.1007/s15010-025-02474-3.


Emergence of population heterogeneity in Klebsiella pneumoniae with a bla-harboring plasmid: carbapenem resistance, virulence, and fitness.

Cho Y, Kim S, Ko K J Biomed Sci. 2025; 32(1):22.

PMID: 39953534 PMC: 11829361. DOI: 10.1186/s12929-024-01108-4.


Effectiveness of antimicrobial agent combinations against carbapenem-producing with KPC variants in China.

Liu C, Wu Y, Zhang Y, Yan Z, Gu D, Zhou H Front Microbiol. 2025; 15:1519319.

PMID: 39911707 PMC: 11794265. DOI: 10.3389/fmicb.2024.1519319.


References
1.
Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M . Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med. 2005; 165(12):1430-5. DOI: 10.1001/archinte.165.12.1430. View

2.
Gregory C, Llata E, Stine N, Gould C, Santiago L, Vazquez G . Outbreak of carbapenem-resistant Klebsiella pneumoniae in Puerto Rico associated with a novel carbapenemase variant. Infect Control Hosp Epidemiol. 2010; 31(5):476-84. DOI: 10.1086/651670. View

3.
Yigit H, Queenan A, Anderson G, Domenech-Sanchez A, Biddle J, Steward C . Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001; 45(4):1151-61. PMC: 90438. DOI: 10.1128/AAC.45.4.1151-1161.2001. View

4.
Sanchez-Romero I, Asensio A, Oteo J, Munoz-Algarra M, Isidoro B, Vindel A . Nosocomial outbreak of VIM-1-producing Klebsiella pneumoniae isolates of multilocus sequence type 15: molecular basis, clinical risk factors, and outcome. Antimicrob Agents Chemother. 2011; 56(1):420-7. PMC: 3256054. DOI: 10.1128/AAC.05036-11. View

5.
Correa L, Martino M, Siqueira I, Pasternak J, Gales A, Silva C . A hospital-based matched case-control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infection. BMC Infect Dis. 2013; 13:80. PMC: 3574843. DOI: 10.1186/1471-2334-13-80. View